News

Anna Vassall shared her experiences in supporting policy decisions throughout different phases of the Covid-19 pandemic in a recent CHDS seminar. Vassall directs the Global Health

A new interactive webtool can estimate future U.S. tuberculosis (TB) and latent TB infection (LTBI) cases in US states. Nicole Swartwood, Research Analyst in CHDS Faculty Nicolas Menzies’ lab, is leading

CHDS Deputy Director Lisa A. Robinson will lead her professional development course, Benefit-Cost Analysis: Valuing Life and Health online from September 19 through 23, 2022. Benefit-cost analysis is an

CHDS Senior Research Scientist Nicole Campos ’ modeling study shows that cervical cancer screening uptake among African-American women in the Mississippi Delta may improve and be cost-effective

Jeremy Goldhaber-Fiebert discussed his work on informing COVID-19 policy decisions at a recent CHDS seminar. Goldhaber-Fiebert is a Professor of Health Policy at Stanford and

The 2022 Society for Benefit-Cost Analysis annual conference will feature research conducted by several CHDS research teams. For example, Lisa Robinson, CHDS Deputy Director and Senior

CHDS PhD candidate John Giardina published an article in JAMA Network Open on “off-ramps” and “on-ramps” for masking and other COVID-19 transmission mitigation

Jagpreet Chhatwal presented a suite of COVID-19 simulation tools at the January 18, 2022, CHDS seminar. Chhatwal is the Associate Director of the MGH Institute for Technology Assessment and Assistant

Recently published research by CHDS’ Yuli (Lily) Hsieh and colleagues evaluated the effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States. When

Maurice Smith discussed the human brain’s control of motor behavior and learning in a recent CHDS seminar. Smith is Professor of Bioengineering at the Harvard Paulson School of Engineering and